Journal of Medicinal Chemistry · 2014 · 20 citations · 31 references
Pharmaceutical ScienceChemoprevention StrategyCellular PharmacologyPharmacotherapyTranslational PharmacologyMolecular PharmacologyMedicinal ChemistryCancer Cell BiologySolomonsterols AAnti-cancer AgentCancer MetabolismBiochemistryBazedoxifene-scaffold-based MimeticsPharmacological AgentDrug DevelopmentPregnane X ReceptorPharmacologyPxr ExpressionNatural SciencesActive Pxr AntagonistMedicineSmall MoleculesDrug Discovery
Pregnane X receptor (PXR), a member of the NR1I nuclear receptor family, acts as a xenobiotic sensor and a paramount transcriptional regulator of drug-metabolizing enzymes and transporters. The overexpression of PXR in various cancer cells indicates the importance of PXR as a drug target for countering multidrug resistance in anticancer treatments. We describe the discovery of novel bazedoxifene-scaffold-based PXR antagonists inspired by the marine sulfated steroids solomonsterol A and B as natural leads. A luciferase reporter assay on a PXR-transfected HepG2 cell line identified compounds 19-24 as promising PXR antagonists. Further structure-activity relationship studies of the most active PXR antagonist from the series (compound 20, IC50 = 11 μM) revealed the importance of hydroxyl groups as hydrogen-bond donors for PXR antagonistic activity. PXR antagonists 20 and 24 (IC50 = 14 μM), in addition to the downregulation of PXR expression, exhibited inhibition of PXR-induced CYP3A4 expression, which illustrates their potential to suppress PXR-regulated phase-I drug metabolism.
31
Paul C. D. Hawkins, A. Geoffrey Skillman, Gregory L. Warren et al. · Journal of Chemical Information and Modeling · 2010 · 1.6K citations · Full text
Structural Bioinformatics, Biomolecular Structure Prediction, Molecular Biology +16